Table 3.
A summary of ranges of reported overall incidence rates and standardized incidence ratios of a number of cancer types following liver transplantation[2-5,7-12,14-16,28,36,47,66,110,118-120]
| Incidence (%) | SIR | |
| Skin cancers | ||
| Represent 24%-54% of all cancers, average 37% | ||
| Overall (non-melanoma) | 0.9-11.6 | 2.1-70, average 24 |
| Squamous cell cancer | 0.6-15.3 | Not reported |
| Basal cell cancer | 0.6-10.6 | Not reported |
| KS | 0.2-1.4 | 128-144 |
| Melanoma | 0.2-3.9 | 4.4 |
| Post-transplant lymphoproliferative disorders | ||
| Represent 4%-57% of all cancers, average 25% | ||
| Overall | 0.5-2.9 | 3.9-21, average 12 |
| Hodgkin’s lymphoma | 0.001-0.4 | 8.2-8.9 |
| Non-Hodgkin's lymphoma | 0.8-3.7 | 3.5-37.3 |
| Solid organ cancers | ||
| Represent 24%-75% of all cancers, average 48% | ||
| Overall | 1.4-7.5 | 1.4-3.1, average 2.3 |
| Lip | 1.8 | 14-24.8 |
| Oropharyngeal | 1.7-1.9 | 7-10 |
| Lung | 0.6-2.4 | 1.4-2.0 |
| Stomach | 0.2-0.7 | 0.5-3.7 |
| Colorectal | 0.5-1.1 | 1.4-4.9 |
| Breast (in females) | 0.2-0.6 | 0.6-1.61 |
| Cervix (in females) | 0.7-1.4 | 1.3-5.7 |
| Prostate (in males) | 0.2-1.8 | 0.6-1.61 |
1
The SIR was not found to be significantly higher for transplant recipients compared with the reference population. Of note, studies often reported either incidence rate or SIR, but rarely both values. SIR: Standardized incidence ratio; KS: Kaposi’s sarcoma.